Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 16, 2022
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN studyHirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
International Journal of Hematology|May 10, 2002
Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndromeKrishnan Allampallam, Vilasini Shetty, Suneel Mundle, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 22, 2026
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE StudyDingwei Ye, Marniza Saad, Ji Youl Lee, et al.
European Urology|December 18, 2019
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE StudyNobuaki Matsubara, Kim N Chi, Mustafa Özgüroğlu, et al.
The Lancet. Oncology|April 17, 2019
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trialKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Asian Journal of Andrology|July 14, 2021
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trialByung Ha Chung, Jian Huang, Zhang-Qun Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASUYoshitaka Honma, Nobuya Monden, Keisuke Yamazaki, et al.
Asian Journal of Andrology|June 16, 2023
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trialByung Ha Chung, Jian Huang, Hiroji Uemura, et al.
Pageof 2